A study to investigate the safety, tolerability, and efficacy of AZD0120 in adults with Refractory SLE

Trial Identifier: D8313C00001
Sponsor: AstraZeneca
Start Date: April 2025
Primary Completion Date: May 2029
Study Completion Date: May 2029
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Darlinghurst, AU, 2010
AU Melbourne, AU, 3000
US, CA San Francisco, CA, US, 94143
US, California Standord, California, US, 94304-2201
US, FL Tampa, FL, US, 33612
US, GA Atlanta, GA, US, 30322
US, MA Boston, MA, US, 02115
US, MO Saint Louis, MO, US, 63110
US, NC Chapel Hill, NC, US, 27599-7280
US, NC Charlotte, NC, US, 28204
US, New York Syracuse, New York, US, 13202-2240
US, NY New York, NY, US, 10032
US, VA Richmond, VA, US, 23298
US, WA Seattle, WA, US, 98195
US, WA Seattle, WA, US, 98104